Drug intelligence / Profile preview

P24FC

Development stage: Preclinical
Lead developer: Immuno Cure BioTech
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Injection

Overview

P24FC is referenced as a DNA vaccine candidate, more specifically as a DNA dendritic cell-targeting vaccine. It has been described in the context of research on vaccines against infectious diseases; “P24FC/EP DNA DC-targeting vaccine” is noted in research discussing immunological responses, likely referring to a DNA vaccine encoding the HIV-1 p24 antigen, modified with a targeting sequence (such as an Fc fragment for dendritic cell targeting) to enhance immunogenicity. Mechanistic and clinical data beyond this research context are not available.

Targets

p24 (HIV-1 capsid protein p24)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on P24FC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P24FC.

Explore the full profile